Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction

© 2018 John Wiley & Sons, Inc. All rights reserved. Toxgnostics is an emerging term within the field of oncology. Currently, the systemic treatment of solid tumors often produces only a modest increase in survival rates, while concomitantly exposing the patient to a very real prospect of significant and potentially life-threatening toxicity. One example can be found in the management of stage 2 colorectal cancer. Toxgnostics is a more agnostic approach to identify germ line variants that influence toxicity. In the field of oncology, as with other specialties, there exists an abundance of practical guidance as to how best the clinician can deliver patient care. Chemotherapy prescription, due to its nature of prescribing highly toxic chemicals, has perhaps more guidance than most inhospital treatments. The aim of toxgnostics is to be able to apply any necessary modifications to a personalized prescription in a prospective manner, therefore mitigating any risks before the patient is exposed.